Zacks Investment Research lowered shares of Bioline RX Ltd (NASDAQ:BLRX) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning, Analyst Ratings Network.com reports.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

Other equities research analysts have also issued research reports about the stock. Roth Capital reaffirmed a buy rating and set a $7.00 target price on shares of Bioline RX in a report on Tuesday, January 12th. Maxim Group reissued a buy rating and set a $4.00 price target on shares of Bioline RX in a research report on Monday, November 16th. Five investment analysts have rated the stock with a buy rating, The company has an average rating of Buy and a consensus price target of $4.40.

Bioline RX (NASDAQ:BLRX) traded up 3.00% on Tuesday, reaching $1.03. 96,562 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $1.17 and a 200-day moving average of $1.46. Bioline RX has a one year low of $0.85 and a one year high of $3.28. The stock’s market cap is $56.29 million.

Bioline RX (NASDAQ:BLRX) last released its earnings results on Monday, November 16th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.05. During the same quarter in the previous year, the business posted ($0.02) EPS. Equities research analysts forecast that Bioline RX will post ($0.27) EPS for the current fiscal year.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

12 Month Chart for NASDAQ:BLRX

Get a free copy of the Zacks research report on Bioline RX (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bioline RX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX Ltd and related companies with MarketBeat.com's FREE daily email newsletter.